A wnaiff yr Ysgrifennydd Cabinet gadarnhau a yw'r therapi golygu genynnau Casgevy (exagamglogene autotemcel) bellach ar gael i gleifion cymwys â chlefyd y crymangelloedd a thalassemia beta sy'n ddibynnol ar drallwysiad yng Nghymru?
Wedi'i ateb gan Ysgrifennydd y Cabinet dros Iechyd a Gofal Cymdeithasol | Wedi'i ateb ar 22/04/2025
In line with recommendations by the National Institute for Health and Care Excellence, Exagamglogene Autotemcel is available for eligible Welsh patients for both transfusion dependent beta-thalassaemia and sickle cell disease, through referral by haematology teams to designated specialised centres.